Arvinas (ARVN) Net Income Growth (3y) (2020 - 2026)
Powered by 
Analysis
Arvinas (ARVN) Net Income Growth (3y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 116.82% |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 17.25% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 37.89% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 37.44% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -38.56% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 62.15% |
| 10 | Arvinas | 609.44 Mn | 41.54 Mn | - | 66.24% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 66.24% |
| Mar 31, 2026 | 10.67% |
| Dec 31, 2025 | 5.59% |
| Sep 30, 2025 | 17.84% |
| Jun 30, 2025 | 3.21% |
| Mar 31, 2025 | 49.73% |
| Dec 31, 2024 | 0.73% |
| Sep 30, 2024 | -1.68% |
| Jun 30, 2024 | 11.22% |
| Mar 31, 2024 | -19.18% |
| Dec 31, 2023 | -58.64% |
| Sep 30, 2023 | -27.32% |
| Jun 30, 2023 | -36.75% |
| Mar 31, 2023 | -53.99% |
| Dec 31, 2022 | -54.68% |
| Sep 30, 2022 | -126.36% |
| Jun 30, 2022 | -57.26% |
| Mar 31, 2022 | -60.97% |
| Dec 31, 2021 | -42.98% |
| Sep 30, 2021 | -51.77% |